His point about the "slow boat" is around the B Cell platform. IMU has been conducting the clinical trial very fast as evidence by the achievement in the last 14 months, this is why the R&D expenditure has been high.
Conducting clinical trial is expensive especially if you are conducting 3 in parallel which is why IMU has $45M in total R&D rebate outstanding. Ph2 clinical trial will be even more expensive and extremely expensive for Ph3 clinical trial but IMU are planning for registrational clinical trial, i.e. Ph2/3, which will allow them to use data from Ph2 clinical trial for regulatory approval so will be much cheaper and faster. This is what BP want so IMU will need to produce more data to get to that development stage.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)